Clinical Trial: Determination of Remifentanil's ED50 for Rapid Sequence Intubation Avoiding Bradycardia and Hypotension in Adults

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title: Determination of Remifentanil's ED50 for Rapid Sequence Intubation Avoiding Bradycardia and Hypotension in Adults

Brief Summary: This study will find the median effective dose of remifentanil for rapid sequence intubation which avoids bradycardia and hypotension

Detailed Summary:

Remifentanil is becoming popular for rapid sequence intubation because it has a fast onset and ultra-short half-life.

Remifentanil a potent opioid associated to bradycardia and hypotension at high doses.


Sponsor: Brasilia University Hospital

Current Primary Outcome: hemodynamic stability during rapid sequence intubation [ Time Frame: from anesthesia induction up to 5 minutes ]

no bradycardia and no hypotension


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Brasilia University Hospital

Dates:
Date Received: February 22, 2017
Date Started: February 25, 2017
Date Completion: March 1, 2017
Last Updated: February 24, 2017
Last Verified: February 2017